Investors

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that the Company has issued 358,772 options over new ordinary shares with an exercise price of 11 pence per share (“New Options”) to Sofia Kolyda, a Director of the Company.

The New Options expire on 6 August 2035 with 269,079 of the New Options vesting on the first anniversary of the options being granted being 6 August 2026 and the balance (comprising 89,693 New Options) vesting once the Company signs a commercial agreement with a partner providing equal or greater than £100k revenues per annum for products containing SweetBiotix.

The issue of the New Options follows the expiration of 358,772 options of ordinary shares granted to Sofia Kolyda which expired in March 2025 of which 75% had vested.

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc		www.optibiotix.com
Neil Davidson, Chairman	Contact via Walbrook below
Stephen O'Hara, Chief Executive
Cairn Financial Advisers LLP (NOMAD and Broker)		Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Walbrook PR Ltd		Mob: 07876 741 001
Anna Dunphy

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Sofia Kolyda
2	Reason for notification
a.	Position/Status	Director
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	OptiBiotix Health Plc
b.	LEI
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 2p each   ISIN: GB00BP0RTP38
b.	Nature of the transaction	Issue of options pursuant to the New Options
c.	Price(s) and volume(s)
			Price(s) per share	Volume(s)
			11p	358,772
d.	Aggregated information -          Volume -          Price	N/A
e.	Date of the transaction	6 August 2025
f.	Place of the transaction	London